124 related articles for article (PubMed ID: 37292763)
1. Chronic activation of tubulin tyrosination in HCM mice and human iPSC-engineered heart tissues improves heart function.
Pietsch N; Chen CY; Kupsch S; Bacmeister L; Geertz B; Herera-Rivero M; Voß H; Krämer E; Braren I; Westermann D; Schlüter H; Mearini G; Schlossarek S; van der Velden J; Caporizzo MA; Lindner D; Prosser BL; Carrier L
bioRxiv; 2024 Feb; ():. PubMed ID: 37292763
[No Abstract] [Full Text] [Related]
2. Depletion of Vasohibin 1 Speeds Contraction and Relaxation in Failing Human Cardiomyocytes.
Chen CY; Salomon AK; Caporizzo MA; Curry S; Kelly NA; Bedi K; Bogush AI; Krämer E; Schlossarek S; Janiak P; Moutin MJ; Carrier L; Margulies KB; Prosser BL
Circ Res; 2020 Jul; 127(2):e14-e27. PubMed ID: 32272864
[TBL] [Abstract][Full Text] [Related]
3. Translational investigation of electrophysiology in hypertrophic cardiomyopathy.
Flenner F; Jungen C; Küpker N; Ibel A; Kruse M; Koivumäki JT; Rinas A; Zech ATL; Rhoden A; Wijnker PJM; Lemoine MD; Steenpass A; Girdauskas E; Eschenhagen T; Meyer C; van der Velden J; Patten-Hamel M; Christ T; Carrier L
J Mol Cell Cardiol; 2021 Aug; 157():77-89. PubMed ID: 33957110
[TBL] [Abstract][Full Text] [Related]
4. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.
Stöhr A; Friedrich FW; Flenner F; Geertz B; Eder A; Schaaf S; Hirt MN; Uebeler J; Schlossarek S; Carrier L; Hansen A; Eschenhagen T
J Mol Cell Cardiol; 2013 Oct; 63():189-98. PubMed ID: 23896226
[TBL] [Abstract][Full Text] [Related]
5. Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.
Flenner F; Geertz B; Reischmann-Düsener S; Weinberger F; Eschenhagen T; Carrier L; Friedrich FW
J Physiol; 2017 Jun; 595(12):3987-3999. PubMed ID: 28090637
[TBL] [Abstract][Full Text] [Related]
6. Slower Calcium Handling Balances Faster Cross-Bridge Cycling in Human
Pioner JM; Vitale G; Steczina S; Langione M; Margara F; Santini L; Giardini F; Lazzeri E; Piroddi N; Scellini B; Palandri C; Schuldt M; Spinelli V; Girolami F; Mazzarotto F; van der Velden J; Cerbai E; Tesi C; Olivotto I; Bueno-Orovio A; Sacconi L; Coppini R; Ferrantini C; Regnier M; Poggesi C
Circ Res; 2023 Mar; 132(5):628-644. PubMed ID: 36744470
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.
Wijnker PJ; Friedrich FW; Dutsch A; Reischmann S; Eder A; Mannhardt I; Mearini G; Eschenhagen T; van der Velden J; Carrier L
J Mol Cell Cardiol; 2016 Aug; 97():82-92. PubMed ID: 27108529
[TBL] [Abstract][Full Text] [Related]
8. Muscle LIM Protein Force-Sensing Mediates Sarcomeric Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy.
Riaz M; Park J; Sewanan LR; Ren Y; Schwan J; Das SK; Pomianowski PT; Huang Y; Ellis MW; Luo J; Liu J; Song L; Chen IP; Qiu C; Yazawa M; Tellides G; Hwa J; Young LH; Yang L; Marboe CC; Jacoby DL; Campbell SG; Qyang Y
Circulation; 2022 Apr; 145(16):1238-1253. PubMed ID: 35384713
[TBL] [Abstract][Full Text] [Related]
9. Characterization of heterozygous and homozygous mouse models with the most common hypertrophic cardiomyopathy mutation MYBPC3
Hilderink S; Schuldt M; Goebel M; Jansen VJ; Manders E; Moorman S; Dorsch LM; van Steenbeek FG; van der Velden J; Kuster DWD
J Mol Cell Cardiol; 2023 Dec; 185():65-76. PubMed ID: 37844837
[TBL] [Abstract][Full Text] [Related]
10. Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium-glucose cotransporter 2 inhibitors.
Wijnker PJM; Dinani R; van der Laan NC; Algül S; Knollmann BC; Verkerk AO; Remme CA; Zuurbier CJ; Kuster DWD; van der Velden J
Cardiovasc Res; 2024 Mar; 120(3):301-317. PubMed ID: 38240646
[TBL] [Abstract][Full Text] [Related]
11. Phosphomimetic cardiac myosin-binding protein C partially rescues a cardiomyopathy phenotype in murine engineered heart tissue.
Dutsch A; Wijnker PJM; Schlossarek S; Friedrich FW; Krämer E; Braren I; Hirt MN; Brenière-Letuffe D; Rhoden A; Mannhardt I; Eschenhagen T; Carrier L; Mearini G
Sci Rep; 2019 Dec; 9(1):18152. PubMed ID: 31796859
[TBL] [Abstract][Full Text] [Related]
12. Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-β-Blocking R-Enantiomer Carvedilol.
Seo K; Yamamoto Y; Kirillova A; Kawana M; Yadav S; Huang Y; Wang Q; Lane KV; Pruitt BL; Perez MV; Bernstein D; Wu JC; Wheeler MT; Parikh VN; Ashley EA
Circulation; 2023 Nov; 148(21):1691-1704. PubMed ID: 37850394
[TBL] [Abstract][Full Text] [Related]
13. The role of α-tubulin tyrosination in controlling the structure and function of hippocampal neurons.
Hosseini S; van Ham M; Erck C; Korte M; Michaelsen-Preusse K
Front Mol Neurosci; 2022; 15():931859. PubMed ID: 36340693
[TBL] [Abstract][Full Text] [Related]
14. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients.
Wu H; Yang H; Rhee JW; Zhang JZ; Lam CK; Sallam K; Chang ACY; Ma N; Lee J; Zhang H; Blau HM; Bers DM; Wu JC
Eur Heart J; 2019 Dec; 40(45):3685-3695. PubMed ID: 31219556
[TBL] [Abstract][Full Text] [Related]
15. The detyrosination/re-tyrosination cycle of tubulin and its role and dysfunction in neurons and cardiomyocytes.
Sanyal C; Pietsch N; Ramirez Rios S; Peris L; Carrier L; Moutin MJ
Semin Cell Dev Biol; 2023 Mar; 137():46-62. PubMed ID: 34924330
[TBL] [Abstract][Full Text] [Related]
16. Defective tubulin detyrosination causes structural brain abnormalities with cognitive deficiency in humans and mice.
Pagnamenta AT; Heemeryck P; Martin HC; Bosc C; Peris L; Uszynski I; Gory-Fauré S; Couly S; Deshpande C; Siddiqui A; Elmonairy AA; ; ; Jayawant S; Murthy S; Walker I; Loong L; Bauer P; Vossier F; Denarier E; Maurice T; Barbier EL; Deloulme JC; Taylor JC; Blair EM; Andrieux A; Moutin MJ
Hum Mol Genet; 2019 Oct; 28(20):3391-3405. PubMed ID: 31363758
[TBL] [Abstract][Full Text] [Related]
17. FHL2 expression and variants in hypertrophic cardiomyopathy.
Friedrich FW; Reischmann S; Schwalm A; Unger A; Ramanujam D; Münch J; Müller OJ; Hengstenberg C; Galve E; Charron P; Linke WA; Engelhardt S; Patten M; Richard P; van der Velden J; Eschenhagen T; Isnard R; Carrier L
Basic Res Cardiol; 2014; 109(6):451. PubMed ID: 25358972
[TBL] [Abstract][Full Text] [Related]
18. Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes.
Tanaka A; Yuasa S; Mearini G; Egashira T; Seki T; Kodaira M; Kusumoto D; Kuroda Y; Okata S; Suzuki T; Inohara T; Arimura T; Makino S; Kimura K; Kimura A; Furukawa T; Carrier L; Node K; Fukuda K
J Am Heart Assoc; 2014 Nov; 3(6):e001263. PubMed ID: 25389285
[TBL] [Abstract][Full Text] [Related]
19. A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.
Seeger T; Shrestha R; Lam CK; Chen C; McKeithan WL; Lau E; Wnorowski A; McMullen G; Greenhaw M; Lee J; Oikonomopoulos A; Lee S; Yang H; Mercola M; Wheeler M; Ashley EA; Yang F; Karakikes I; Wu JC
Circulation; 2019 Feb; 139(6):799-811. PubMed ID: 30586709
[TBL] [Abstract][Full Text] [Related]
20. Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice.
Fraysse B; Weinberger F; Bardswell SC; Cuello F; Vignier N; Geertz B; Starbatty J; Krämer E; Coirault C; Eschenhagen T; Kentish JC; Avkiran M; Carrier L
J Mol Cell Cardiol; 2012 Jun; 52(6):1299-307. PubMed ID: 22465693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
